May 18 - 21, 2019
Grand Hyatt Denver
Denver, Colorado, USA
Abstract submission deadline: Wednesday, February 20
Advance registration deadline: Monday, April 8
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 17.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, July 2, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the AACR on this site and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Bladder cancer is among the most prevalent cancers worldwide, with approximately 430,000 new diagnoses each year. Mortality from bladder cancer remained stagnant for nearly 30 years. Additionally, white light cystoscopy, which is a painful and expensive invasive procedure, is the current standard method in the diagnosis and follow-up of bladder cancer.
However, the clinical management and diagnoses of bladder cancer are poised for rapid change due to recent advances in large-scale gene expression and sequencing efforts, systemic immunotherapies, and the discovery of novel biomarkers. This conference will address these advances and showcase cutting-edge research that continues to push the progress of clinical treatments forward.
This will be the first AACR Special Conference on Bladder Cancer. This multidisciplinary program will span from basic research to clinical care. The plenary sessions on management of non-invasive disease, neoadjuvant and bladder-sparing approaches to invasive disease, and management of metastatic disease are likely to be of particular interest to clinicians.
After participating in this CME activity, physicians should be able to:
1. Assess the molecular tools used in the discovery and validation of biomarkers and driver genes in bladder cancer.2. Identify new areas for collaborative study among bladder cancer surgeons, clinicians, radiation oncologists, and basic researchers.3. Compare the benefits and drawbacks of cutting-edge cellular and animal models available to study the biological behavior of bladder cancer.4. Describe the mechanisms of action underlying therapies used to treat patients with bladder cancer in various stages of disease (non-invasive, invasive, metastatic), and understand the basics of their molecular rationale.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by Professional Educational Grants and will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or email@example.com.